Cited 3 times in
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박승우 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 정문재 | - |
dc.date.accessioned | 2015-01-06T17:19:58Z | - |
dc.date.available | 2015-01-06T17:19:58Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99781 | - |
dc.description.abstract | PURPOSE: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. METHODS: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m(2), twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. RESULTS: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75%) had extrahepatic cholangiocarcinoma, two patients (10%) had intrahepatic cholangiocarcinoma, and three patients (15%) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15%), and stable disease was achieved in 14 patients (70%). The overall response rate was 15%, and the disease stabilization rate was 85%. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15%), neutropenia (10%), and nausea (10%). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. CONCLUSIONS: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 861~865 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Biliary Tract Neoplasms/drug therapy* | - |
dc.subject.MESH | Biliary Tract Neoplasms/pathology | - |
dc.subject.MESH | Chemoradiotherapy/methods* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Drug Screening Assays, Antitumor | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Oxonic Acid*/administration & dosage | - |
dc.subject.MESH | Oxonic Acid*/adverse effects | - |
dc.subject.MESH | Pilot Projects | - |
dc.subject.MESH | Tegafur*/administration & dosage | - |
dc.subject.MESH | Tegafur*/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hee Man Kim | - |
dc.contributor.googleauthor | Kyong Joo Lee | - |
dc.contributor.googleauthor | Jihye Cha | - |
dc.contributor.googleauthor | Moon Jae Chung | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.identifier.doi | 10.1007/s00280-014-2565-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A03602 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 25129491 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-014-2565-y | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | Biliary tract cancer | - |
dc.subject.keyword | Concurrent chemoradiotherapy | - |
dc.subject.keyword | Pilot | - |
dc.contributor.alternativeName | Park, Seung Woo | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Chung, Moon Jae | - |
dc.contributor.affiliatedAuthor | Park, Seung Woo | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Chung, Moon Jae | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 74 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 861 | - |
dc.citation.endPage | 865 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.74(4) : 861-865, 2014 | - |
dc.identifier.rimsid | 49595 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.